Stem cell controversy – Wikipedia

Ethical controversy over the use of embryonic stem cells The stem cell controversy is the consideration of the ethics of research involving the development and use of human embryos. Most commonly, this controversy focuses on embryonic stem cells. Not all stem cell research involves human embryos

Read more
Regenerative therapy linked to QOL benefit for patients with SUI – Urology Times

Stress urinary incontinence is a consistent health issue in female patients that is typically treated with surgical interventions. Clinicians have investigated less invasive treatments for this debilitating condition, but the question is whether they are safe and produce positive results. In a recent study presented at the 2021 American Urological Association Annual Meeting, Melissa R.

Read more
Stem Cell Differentiation | Stem Cells | Tocris Bioscience

Stem Cell Differentiation Target Files Stem cell differentiation involves the changing of a cell to a more specialized cell type, involving a switch from proliferation to specialization. This involves a succession of alterations in cell morphology, membrane potential, metabolic activity and responsiveness to certain signals

Read more
Stem cell project to create new model to study brain development and Down syndrome – University of Wisconsin-Madison

University of WisconsinMadison Waisman Center researchers are creating a new approach to study how changes to brain development in the womb result in intellectual disability in people with Down syndrome. Their efforts, funded by an $11 million Transformative Research grant from the National Institutes of Health, may also reveal how brain development in individuals with Down syndrome differs from typically developing individuals, identify features that will help understand their intellectual disability, and find potential targets for therapy.

Read more
OrganaBio Adds Perinatal and Adult Tissues for Clinical Manufacturing to its Portfolio of Products for Allogeneic Cell Therapy Development – Yahoo…

MIAMI, October 08, 2021--(BUSINESS WIRE)--OrganaBio, LLC ("OrganaBio") is expanding its product portfolio with the addition of current Good Manufacturing Practices (cGMP)- and current Good Tissue Practices (cGTP)-compliant perinatal umbilical cord blood and leukopak products. Obtained from fully consented donors, under IRB-approved protocols, with comprehensive testing and supporting documentation to meet the regulatory requirements of the US FDA and other regulatory agencies, OrganaBios cGMP compliant products further deliver on OrganaBios commitment to providing high quality critical starting materials to cell therapy and cancer immunotherapy developers. Marketed under the HematoPAC-GMP and LeukoPAC-GMP brands, these products are a source of hematopoietic stem cells (HSCs) and lymphoid- and myeloid-derived immune cells, including T, NK, T-reg, gamma delta T cells, macrophages, and B cells, which are critical raw materials for allogeneic regenerative medicine, cell therapy, and immunotherapy development and manufacturing

Read more